Sun Pharmaceutical Industries announced that one of its wholly-owned
subsidiaries has commercialized CEQUA (cyclosporine ophthalmic solution) 0.09% in the U.S.
CEQUA, which offers the highest concentration of cyclosporine for ophthalmic use approved by the
U.S. Food and Drug Administration (FDA), is indicated to increase tear production in patients with
keratoconjunctivitis sicca (dry eye), an inflammatory disease that afflicts more than 16 million people
in the U.S.1 CEQUA is the first and only FDA-approved cyclosporine treatment delivered with
nanomicellar (NCELL) technology, which helps to improve the bioavailability and physicochemical
stability of cyclosporine, resulting in improved ocular tissue penetration.
Powered by Capital Market - Live News
Disclaimer: No Business Standard Journalist was involved in creation of this content
